Last edition
News about "GSK HS235 pulmonary hypertension"
GSK Acquires 100 Percent Equity of 35Pharma for USD 950 Million
GSK completes acquisition of 35Pharma, adding HS235, a potential best-in-class therapy for Pulmonary Hypertension.
GSK HS235 Pulmonary Hypertension | 16/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members